BBO-10203, a first-in-class breaker of the PI3Kα:RAS interaction, demonstrates in vitro and in vivo efficacy alone or in combination with standard-of-care therapies in solid[...]

Bridgebio Oncology Therapeutics Inc. published this content on October 29, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2025 at 12:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]